Clinical trials: Satisfaction Survey
Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007).
- Trial name
- NCT06680206
- Testing
- Rimegepant, Triptans
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Pfizer